

**CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8**

I hereby certify that on Monday February 14, 2005, the following correspondence pertaining to U.S. Patent Application Number 09/546,573, is being transmitted to Examiner S. L. Rawlings, Ph.D. at the U.S. Patent and Trademark Office to facsimile number (703) 872-9306:

(1) Copy of:

(a) Supplemental Amendment  
Under 37 C.F.R. 1.111

**RECEIVED  
CENTRAL FAX CENTER**


**FEB 14 2005**

February 14, 2005

Date

Stacey A. Chandler

Typed or printed name of person signing Certificate

  
Signature

**Note:** Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

PATENT  
ATTORNEY DOCKET NO 59866.000002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**RECEIVED**  
**CENTRAL FAX CENTER**

In re Patent Application of:

M. N. Holten-Andersen et al.

Serial No.: 09/546,573

Filed: April 10, 2000

Confirmation No.: 3408

Art Unit: 1642

Examiner: S. L. Rawlings, Ph.D.

FEB 14 2005

For: TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES  
TYPE-1 (TIMP-1) AS A CANCER MARKER**SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. §1.111****Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**I. Introductory Comments**

In response to the Office Action of July 2, 2004, and supplemental to the Amendment Under 37 C.F.R. § 1.111, filed November 2, 2004, please amend the above-identified patent application as set forth below:

Amendments to the claims begin at page 2 of this document.

Remarks begin at page 12 of this document.